Abstract
Pediatric rheumatic diseases (PRD) encompass an heterogeneous group of rare diseases, ranging from juvenile idiopathic arthritis (JIA), juvenile systemic lupus erythematosus (JSLE) to juvenile dermatomyositis (JDM) and others. The PRD constitute a small market which is of little interest for pharmaceutical industries. Difficulties in operating in this specific area relate to problems which are peculiar to children, such as specific methods for the assessment of the primary outcome, or paediatric formulations, with the need of setting large networks in order to collect in a reasonable time frame an adequate number of patients.
| Original language | English |
|---|---|
| Pages (from-to) | 105-107 |
| Number of pages | 3 |
| Journal | Pharmaceuticals Policy and Law |
| Volume | 12 |
| Issue number | 1-2 |
| DOIs | |
| Publication status | Published - 2010 |
Fingerprint
Keywords
- JDM
- JIA
- JSLE
- Paediatric
- PRINTO
- rheumatic disease
ASJC Scopus subject areas
- Health Policy
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Cite this
Needs in paediatric Rheumatology : The PRINTO perspective. / Ruperto, Nicolino.
In: Pharmaceuticals Policy and Law, Vol. 12, No. 1-2, 2010, p. 105-107.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Needs in paediatric Rheumatology
T2 - The PRINTO perspective
AU - Ruperto, Nicolino
PY - 2010
Y1 - 2010
N2 - Pediatric rheumatic diseases (PRD) encompass an heterogeneous group of rare diseases, ranging from juvenile idiopathic arthritis (JIA), juvenile systemic lupus erythematosus (JSLE) to juvenile dermatomyositis (JDM) and others. The PRD constitute a small market which is of little interest for pharmaceutical industries. Difficulties in operating in this specific area relate to problems which are peculiar to children, such as specific methods for the assessment of the primary outcome, or paediatric formulations, with the need of setting large networks in order to collect in a reasonable time frame an adequate number of patients.
AB - Pediatric rheumatic diseases (PRD) encompass an heterogeneous group of rare diseases, ranging from juvenile idiopathic arthritis (JIA), juvenile systemic lupus erythematosus (JSLE) to juvenile dermatomyositis (JDM) and others. The PRD constitute a small market which is of little interest for pharmaceutical industries. Difficulties in operating in this specific area relate to problems which are peculiar to children, such as specific methods for the assessment of the primary outcome, or paediatric formulations, with the need of setting large networks in order to collect in a reasonable time frame an adequate number of patients.
KW - JDM
KW - JIA
KW - JSLE
KW - Paediatric
KW - PRINTO
KW - rheumatic disease
UR - http://www.scopus.com/inward/record.url?scp=78049391997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78049391997&partnerID=8YFLogxK
U2 - 10.3233/PPL-2010-0279
DO - 10.3233/PPL-2010-0279
M3 - Article
AN - SCOPUS:78049391997
VL - 12
SP - 105
EP - 107
JO - Pharmaceuticals Policy and Law
JF - Pharmaceuticals Policy and Law
SN - 1389-2827
IS - 1-2
ER -